Darmerica, LLC
Has Darmerica, LLC received an FDA warning letter? Yes. FDA issued a warning letter dated December 8, 2025.
Letter facts
- Letter date
- December 8, 2025 (2025-12-08)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Manufacturer / API
- Products named
- Active pharmaceutical ingredients (APIs)Drugs
- Violation categories
- MisbrandingCGMP / insanitary conditionsFalse or misleading claims
Understanding these violation categories
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA cited Darmerica for CGMP deviations in API repackaging, including inadequate quality unit oversight, deficient supplier qualification, incomplete complaint and recall investigations, and releasing APIs before testing. Drugs were also misbranded due to labeling and listing failures.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- CGMP deviations for APIs (adulterated drugs, 501(a)(2)(B))
- Failure of quality unit oversight
- Inadequate supplier evaluation/qualification
- Inadequate complaint and recall investigations
- Inadequate pre-release testing of APIs
- Misbranding due to false or misleading labeling (502(a))
- Misbranding due to lack of adequate directions for use (502(f)(1))
- Misbranding due to failure to list drugs (502(o))
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (Misbranding)
Recent warning letters with related regulatory findings:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.